noreximide: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65584 |
| SCHEMBL ID | 2109030 |
| MeSH ID | M0101555 |
| Synonym |
|---|
| 6319-06-8 |
| noreximidum [inn-latin] |
| 4,7-methano-1h-isoindole-1,3(2h)-dione, 3a,4,7,7a-tetrahydro-, (3a-alpha,4-beta,7-beta,7a-alpha)- |
| noreximide |
| noreximida [inn-spanish] |
| cis-exo-5-norbornene-2,3-dicarboximide |
| bicyclo(2.2.1)hept-5-ene-2,3-exo-cis-dicarboximide |
| noreximida [spanish] |
| 4,7-methano-1h-isoindole-1,3(2h)-dione, 3a,4,7,7a-tetrahydro-, (3ar,4r,7s,7as)-rel- |
| noreximide [inn] |
| 5-norbornene-2,3-dicarboximide, exo- |
| (cis-exo)-5-norbornene-2,3-dicarboximide |
| NCGC00160680-01 |
| AKOS006279023 |
| nsc 31978 |
| noreximida |
| spy6x504vm , |
| noreximidum |
| unii-spy6x504vm |
| dtxcid6026298 |
| tox21_111983 |
| dtxsid8046298 , |
| cas-6319-06-8 |
| 4,7-methano-1h-isoindole-1,3(2h)-dione, 3a,4,7,7a-tetrahydro-,(3ar,4r,7s,7as)-rel- |
| SCHEMBL2109030 |
| (3ar,4r,7s,7as)-3a,4,7,7a-tetrahydro-1h-4,7-methanoisoindole-1,3(2h)-dione |
| CS-0077645 |
| (1r,2r,6s,7s)-4-azatricyclo[5.2.1.0?,?]dec-8-ene-3,5-dione |
| Q27289333 |
| (1r,2r,6s,7s)-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione |
| rel-(3ar,4r,7s,7as)-3a,4,7,7a-tetrahydro-1h-4,7-methanoisoindole-1,3(2h)-dione |
| Excerpt | Reference | Relevance |
|---|---|---|
| " administration, and the pharmacokinetic parameters were determined from the concentration-time data." | ( Pharmacokinetic evaluation of norendimide in rats. Czejka, M; Koch, HP; Pischek, G; Ritschel, WA, 1982) | 0.26 |
| " The biologic half-life of approximately 8 h was found almost the same for all three routes." | ( Pharmacokinetic evaluation of noreximide in rats. Holzbecher, M; Koch, HP; Pischek, G; Ritschel, WA, ) | 0.42 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The absolute bioavailability is about 50%." | ( Pharmacokinetics of noreximide in the beagle dog. Bykadi, G; Koch, HP; Ledesma, B; Ritschel, WA, 1982) | 0.59 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dosage forms were prepared from 14C-labeled noreximide and cold material." | ( Pharmacokinetics of noreximide in the beagle dog. Bykadi, G; Koch, HP; Ledesma, B; Ritschel, WA, 1982) | 0.84 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||